💥 Gate Square Event: #PostToWinCGN 💥
Post original content on Gate Square related to CGN, Launchpool, or CandyDrop, and get a chance to share 1,333 CGN rewards!
📅 Event Period: Oct 24, 2025, 10:00 – Nov 4, 2025, 16:00 UTC
📌 Related Campaigns:
Launchpool 👉 https://www.gate.com/announcements/article/47771
CandyDrop 👉 https://www.gate.com/announcements/article/47763
📌 How to Participate:
1️⃣ Post original content related to CGN or one of the above campaigns (Launchpool / CandyDrop).
2️⃣ Content must be at least 80 words.
3️⃣ Add the hashtag #PostToWinCGN
4️⃣ Include a screenshot s
Rongchang Bio responds to Pfizer's $200 million impairment of Vidisutuximab: Pfizer's conclusion is based on market competition environment.
On February 7th, Jinshi Data reported that Rongchang Biology responded to the reporter’s inquiry about the devaluation of its vedolizumab (RC48) by its partner Pfizer, which amounted to a reduction of 200 million US dollars. Rongchang Biology stated that this devaluation is due to changes in the market competitive environment compared to the time of the transaction, and some indications for vedolizumab have not progressed as expected, resulting in a decrease in expected value compared to the transaction time. This conclusion was made by Pfizer based on its judgment of the market competitive environment. Previously, in August 2021, Rongchang Biology authorized the overseas rights of its HER2ADC (antibody-drug conjugate) vedolizumab to ADCleading company Seagen. In 2023, Seagen was acquired by Pfizer. Currently, Pfizer is advancing the indication of vedolizumab for urothelial carcinoma overseas.